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MaMyocarditis is a diverse group of heart-speciﬁc immune processes classiﬁed by clinical and histopathological
manifestations. Up to 40% of dilated cardiomyopathy is associated with inﬂammation or viral infection. Recent
experimental studies revealed complex regulatory roles for several microribonucleic acids and T-cell and macrophage
subtypes. Although the prevalence of myocarditis remained stable between 1990 and 2013 at about 22 per 100,000
people, overall mortality from cardiomyopathy and myocarditis has decreased since 2005. The diagnostic and prognostic
value of cardiac magnetic resonance has increased with new, higher-sensitivity sequences. Positron emission tomography
has emerged as a useful tool for diagnosis of cardiac sarcoidosis. The sensitivity of endomyocardial biopsymay be increased,
especially in suspected sarcoidosis, by the use of electrogram guidance to target regions of abnormal signal. Investigational
treatments on the basis of mechanistic advances are entering clinical trials. Revised management recommendations
regarding athletic participation after acute myocarditis have heightened the importance of early diagnosis.
(J Am Coll Cardiol 2016;68:2348–64) © 2016 by the American College of Cardiology Foundation.M yocarditis refers to multiple heart-speciﬁcinﬂammatory conditions with a spectrumof clinical and histopathological manifes-
tations (1). In the late 19thcentury, the termmyocarditis
included myocardial infarction and chronic ischemic
heart disease. The termhas been reﬁned, and presently
applies to acute or chronic inﬂammatory responses of
the heart to environmental or endogenous triggers,
most commonly viruses, and less frequently bacteria,
fungi, and parasites. Important noninfectious causes
include giant cell myocarditis (GCM), drug-induced
hypersensitivity, and cardiac manifestations of sys-
temic autoimmunity, such as sarcoidosis or systemic
lupus erythematosus (2,3). This paper seeks to frame
recent clinical advances in the management of
myocarditis within the latest understanding of patho-
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AB BR E V I A T I O N S
AND ACRONYM S
CMR = cardiac magnetic
resonance
CS = cardiac sarcoidosis
EMB = endomyocardial biopsy
GCM = giant cell myocarditis
IFN = interferon
LGE = late gadolinium
enhancement
LV = left ventricle/ventricular
MyHC = myosin heavy chain
RV = right ventricle/ventricular
TLR = Toll-like receptor
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2349histologically veriﬁed cardiac sarcoidosis (CS) was
diagnosed in 233 patients in Helsinki, Finland (8). The
annual detection rate of CS was 0.6 per 100,000
adults (>18 years of age) in the last full 2-year study
period between 2013 and 2014. The prevalence of CS
in 2012 was 2.2 per 100,000 people. Over the study
period, the detection rate of CS increased more than
50-fold. From case series, CS affects 2.3% to 11% of
patients with sarcoidosis and 2.5% of unexplained
cardiomyopathy in a referral population (diagnosed
by heart biopsy, 31 of 1,235). Asymptomatic sarcoid
heart involvement is more common. In autopsy
studies, myocardial involvement has been seen in
20% to 27% of consecutive sarcoidosis patients (9).
Also, other granulomatous systemic diseases may
involve the heart in a subclinical way. In antinuclear
cytoplasmic antibody-associated vasculitis, cardiac
involvement is found in up to 65% of patients in
remission, the majority caused by nonischemic injury
of the heart (10).
GCM is a rare, rapidly progressive, and clinically
important form of myocarditis (11). The estimated
annual detection rate for GCM in Finland between 2013
and 2014 was 0.13 per 100,000 people (12,13). Over a
23-year period between 1991 and 2015, 55 cases of GCM
were diagnosed. The detection rate increased 10-fold
over this period. The cause for the increased rate of
detection of CS and GCM in Finland is uncertain, and
may be related to increased awareness of the diseases,
increased referral to an advanced heart failure center,
or an increased use of biventricular biopsies over the
study timeframe. In autopsy registries, histological
evidence of GCM was found in up to 6.6 per 100,000FIGURE 1 Myocarditis and Cardiomyopathy Deaths and Death Rates
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Health Metrics and Evaluation.people or 3% to 5.6% of all myocarditis au-
topsies (14,15). In endomyocardial biopsy
(EMB) studies of dilated cardiomyopathy
(DCM) at a tertiary referral center, GCM was
found in 0.2% to 1.2%, and 2% of cardiac
transplant patients had GCM (16).
ETIOLOGY
The most commonly identiﬁed pathogens in
acute myocarditis are viruses (17). The im-
mune response triggered by injury and
autoantigen-speciﬁc mechanisms leads to
organ dysfunction, pathological remodeling,
and heart failure. From the 1950s to the 1990s,
enteroviruses were the most frequently identiﬁed
pathogen, particularly coxsackie virus in North Amer-
ica and Western Europe (18,19). In the past 2 decades,
polymerase chain reaction and in situ hybridization
have identiﬁed a range of cardiotropic viruses,
including H1N1 strains of inﬂuenza (20), adenovirus
(21,22), hepatitis C (23,24), cytomegalovirus, echo-
virus, parvovirus B-19, and Epstein-Barr virus (25) in
heart biopsy samples. In subjects with more chronic
symptoms and “inﬂammatory cardiomyopathy,”
parvovirus B19 (26) and human herpes virus 6 genomes
(27) predominate.
In select populations, speciﬁc nonviral infections
and autoimmune syndromes remain important
causes of myocarditis. Autoimmunity following un-
treated streptococcal infection results in rheumatic
carditis (28). Bacteria, such as diphtheria and Borrelia
burgdorferi (Lyme disease), or parasites, such asFrom 1990 to 2015
B
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2350Trypanosoma cruzi (Chagas disease), are important in
speciﬁc regions (29,30). Hypersensitivity myocarditis
may result from drug- or vaccine-related heart-
speciﬁc autoimmunity. Methyldopa, hydrochlo-
rothiazide, furosemide, ampicillin, tetracycline,
azithromycin, aminophylline, phenytoin, benzodiaz-
epines, tricyclic antidepressants, and tumor necrosis
factor antagonists all have a low rate of myocarditis
(31). Although most cases of hypersensitivity
myocarditis develop early in the course of drug use,
up to 15% of clozapine-induced myocarditis develops
later, up to 2 years after initiation of drug therapy
(32,33). Vaccination against smallpox infection is
associated with myopericarditis in up to 6 per 10,000
vaccines (34). Other noninfectious causes of myocar-
ditis include cardiac inﬂammation in the context of
radiation or systemic autoimmune diseases,
including antinuclear antibody-related vasculitis,
systemic sclerosis, lupus erythematosus, and celiac
disease (35). A total of 20% of GCM patients have a
history of other autoimmune disorders. In GCM, the
risk of transplantation and death has decreased since
the introduction of prompt calcineurin inhibitor–
based immunosuppression (12). Biopsy-documented
GCM recurs up to 8 years after successful treatment
in 12%, in both the native heart and in the allograft
following transplantation (36).
PATHOGENESIS
Most of the current mechanistic understanding of
human myocarditis derives from experiments in
susceptible rodent strains. Inﬂammatory cellular in-
ﬁltrates develop either after cardiomyocyte infection
with a cardiovirulent virus strain (37,38), parasites, or
bacteria, or after delivery of cardiac antigens with a
strong adjuvant or carried within dendritic cells in
noninfectious models (39–41). Models that do not rely
on infection only provide insights to the latter phases
of myocarditis.
The transition from acute viral infection through
active inﬂammation to DCM can be conceptualized as
a multiphase model (Central Illustration). The oppor-
tunities for therapeutic intervention vary by stage of
disease. Depending on the inciting infective agent,
the mechanisms of early tissue injury as well as the
resulting patterns of inﬂammatory mediators and
cytokines differ. In virus-mediated myocarditis, for
example, viral entry into cardiomyocytes leads to the
production of type 1 interferons within hours and to
myocyte death through apoptosis and autophagy
(42). It requires speciﬁc cell surface receptors, such as
the coxsackie-adenovirus receptor and decay-
accelerating factor (CD55) for some coxsackie B virusstrains (43,44). The activity of inﬂammatory signaling
pathways in cardiac myocytes contributes to cox-
sackie B virulence via effects on viral replication
(45,46). The result of the initial damage is presenta-
tion of normally sequestered cardiac protein frag-
ments in the context of tissue damage. The
pathogenesis of myocarditis varies by pathogen. For
example, in Chagas myocarditis, tissue damage
results not only from the associated invasion of
inﬂammatory cells, but also directly, through para-
sites releasing bioactive compounds and promoting
oxidative stress (47). Cardiac parasympathetic neu-
rons are also damaged by the parasite, leading to
unopposed sympathetic activation (48).
A second phase that evolves over hours to days
involves activation of an innate immune response,
consisting of nitric oxide, altered regulatory T-cell
function, natural killer (NK) cells, release of mediators
such as type I interferon in viral myocarditis (49–51), or
granule components from eosinophils and poly-
morphonuclear cells in bacterial and parasitic
myocarditis. The exodus of antigen-bearing cells to
regional lymph nodes within the appropriate cytokine
milieu triggers a third phase, characterized by cellular
cardiac inﬁltrates with pathogen- and autoantigen-
speciﬁc T cells, macrophages, and antibodies (52–54).
Efﬁcient clearance of the infective agent usually re-
sults in recovery of normal cardiac function. In
genetically susceptible experimental animals and
humans, a breakdown of T-cell tolerance to cardiac
self-antigens may occur (37,55,56). This leads to a
process of chronic autoantigen-driven inﬂammation,
which can progress to DCM and end-stage heart failure
(57–60). The signiﬁcance of cardiac autoimmunity in
disease progression depends on genetic susceptibility
of the host, genetic variations of the inciting microbes,
molecular mimicry between cardiac structures and
microbial proteins, and environmental factors. Phases
of autoimmune inﬂammation progression cannot be
triggered only through infective agents, but also
through noninfective microbial particles, heat shock
proteins, or immunogenic fragments released after
tissue injury, drug exposure, or in the context of sys-
temic autoimmune diseases. In the transition from
acute inﬂammation to chronic ﬁbrosis, inﬂammation
can persist in the absence of symptoms (61,62).
CELLULAR AND EXTRACELLULAR
COMPARTMENTS OF
CARDIAC INFLAMMATION
Similar to other organs, different cellular compart-
ments are involved in myocardial inﬂammation
and remodeling: 1) the bone marrow-derived
CENTRAL ILLUSTRATION Multiphase Model of Myocarditis
Acute myocarditis
Quiescent regulatory immune elements (myocytes and dendritic cells)
Regulatory elements restore tolerance:
of heart muscle
Symptoms:
Chest pain
Heart failure
Tachyarrhythmias
Acute cardiomyopathy
• Asymptomatic or mildly decreased
cardiac reserve function
• Possible myocyte hypertrophy
or mild scarring
• Chronic recurrent chest pain
• Progression to cardiomyopathy
with or without viral presence
Pathogenesis:
Antigen bearing cells
macrophages and antibodies
Heymans, S. et al. J Am Coll Cardiol. 2016;68(21):2348–64.
Acute myocarditis results from a variety of injuries that often trigger immune responses to both pathogens and myocardial tissue. Clinical
recovery or progression to chronic cardiomyopathy or to recurrent chest pain depends on the balance of regulatory and effector elements.
Chronic injury may be associated with ongoing viral infection.
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2351compartment, including effector cells of adaptive
immunity, such as T- and B-cells, and a myeloid-
derived population of astonishing plasticity,
including subsets of macrophages, dendritic cells,
granulocytes, eosinophils, mast cells, and an imma-
ture precursor population with the capacity to
differentiate not only into inﬂammatory cells, but
also into myoﬁbroblasts; 2) the endothelial compart-
ment, which serves as a critical barrier regulating the
access of circulating bone-marrow–derived cells to
the heart; 3) the interstitial compartment, consisting
of ﬁbroblasts, myoﬁbroblasts, and other stromal cells,
embedded in an interstitial matrix that contributes to
and interacts with the speciﬁc local milieu to shape
the inﬂammatory phenotype; and, ﬁnally, 4) the
cardiomyocyte compartment, which is not only atarget of early infection, but also shows speciﬁc
adaptive responses to inﬂammatory stimuli, such as
hypertrophy and altered calcium signaling (63,64).
Changes in these cellular compartments following an
inciting event of heart tissue damage, incurred by
infections, toxins, ischemia, or immunological
imbalance, deﬁne the pathological anatomic pheno-
type of the inﬂamed heart. Changes in the cellular
compartments, including activation, deactivation,
or transdifferentiation of speciﬁc cell subsets, are
regulated by cell-cell interactions and by autocrine
and paracrine mediators, including chemokines,
cytokines, hormones, and degradation or danger
products, acting to activate or inhibit gene expres-
sion through more or less speciﬁc receptors
and their intracellular downstream pathways (65).
FIGURE 2 Important Cellular Compartments Involved in Early Myocarditis and Progression to End-Stage Heart Failure
(Left) Early inﬂammation is a predominantly Th1-driven process, with an important role for M1 macrophages. In contrast, M2 macrophages and Th17 responses
characterize late responses. IL-17 is a key cytokine in dilated cardiomyopathy progression. Tip-DCs are key elements of a negative, nitric oxide–dependent feedback loop
limiting effector T-cell responses. (Right) Heart-inﬁltrating monocytic precursors are the cellular source of acute inﬂammation and tissue ﬁbrosis, a hallmark of
end-stage heart failure. BM ¼ bone marrow; DC ¼ dendritic cell; GM-CSF ¼ granulocyte-macrophage colony stimulating factor; IFN ¼ interferon; IL ¼ interleukin;
M-CSF ¼ macrophage colony-stimulating factor; NK ¼ natural killer; Tip-DC ¼ tip-dendritic cell.
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2352Other cellular regulatory mechanisms, such as gene
silencing, contribute to the post-transcriptional
regulation of myocarditis (62). The extracellular ma-
trix, an intricate proteinaceous network that ﬁlls the
extracellular spaces and provides structural support
and tissue organization, is the ﬁfth element that
modulates cardiac inﬂammation, remodeling, and
tissue ﬁbrosis (Figure 2) (66,67).
INNATE MECHANISMS IN MYOCARDITIS AND
INFLAMMATORY CARDIOMYOPATHY
Cells of the innate immune system mainly include
macrophages, granulocytes, dendritic cells, histio-
cytes,mast cells, and eosinophils. These cells present a
broad array of intracellular and surface pattern-
recognition receptors that recognize conserved
microbial structures that are not shared by host mole-
cules (pathogen-associated molecular patterns) (68).In myeloid cells, these pathogen-associated molecular
patterns induce the inﬂammasome, a multiprotein
oligomer including caspase 1, PYCARD, and
nucleotide-binding oligomerization domain (NOD)-
like receptors. Pathogen-associated molecular
patterns also form inﬂammasomes by binding to
intracellular pattern recognition receptors, such as
NOD-like receptor subsets, and to caspase-1. The
inﬂammasome activates the caspase-1 cascade, lead-
ing to production of proinﬂammatory cytokines. In
contrast, Toll-like receptors (TLRs) represent a family
of pattern recognition receptor molecules that are
usually expressed on the cell surface (Figure 2).
TLRs play a key role in the early activation of the
innate immune response against viral and other in-
fections. TLRs are predominantly, but not exclusively,
expressed in macrophages and dendritic cells. Eleven
TLRs have been identiﬁed in humans. Thus far, speciﬁc
roles in inﬂammatory heart disease and myocarditis
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2353have been attributed to TLR2, TLR3, TLR4, TLR7, and
TLR9, and their downstream adaptors, MyD88 and
TRIF (45,69–73). Accordingly, TLR3-deﬁcient mice
show markedly increased mortality after infection
with enteroviruses (74). Interestingly, a common
TLR3 polymorphism has been found in patients
with enteroviral myocarditis/cardiomyopathy (75).
Expression of the TLR3 variant results in signiﬁcantly
reduced TLR3-mediated signaling after exposure to
enterovirus-speciﬁc pathogen-associated molecular
patterns, and promotes viral replication. In non-
ischemic cardiomyopathy, cardiac expression of pro-
tease activated receptor 2 (PAR2), which interacts with
TLR3, correlates positively with inﬂammation and
negatively with interferon (IFN)-b expression and
cardiac function (76).
Activation of TLRs and the inﬂammasome results in
release of cytokines, such as tumor necrosis factor
(TNF)-a, interleukin (IL)-1b, IL-18, or high-mobility
group box 1 protein in myocarditis and DCM (77,78).
TLR2 and TLR4 activation mediates TNF release, and
TLR2, together with TLR4, promotes IL-1b secretion.
Moreover, self-proteins, such as cardiac myosin, can
directly activate TLR2 and TLR4 (79). TLR4 is up-
regulated in macrophages and mast cells during the
early innate immune response following acute cox-
sackie virus B3 infection. In patients with myocarditis,
TLR4 messenger ribonucleic acid (mRNA) expression
is up-regulated and directly correlates with viral ribo-
nucleic acid (RNA) levels. However, TLR4-deﬁcient
mice show reduced cardiac inﬂammation and IL-1b
levels in the heart during acute coxsackie virus B3
myocarditis. The IL-1b axis is directly involved in car-
diac ﬁbrosis, a hallmark of pathological remodeling
and heart failure progression (61). In contrast, high-
mobility group box 1 protein promotes cardiac
inﬂammation in a mouse model of troponin I–induced
experimental autoimmune myocarditis by a complex
interaction involving the receptor for advanced
glycation end products and TLRs (77).
ROLE OF MACROPHAGE SUBSETS IN
MYOCARDITIS DEVELOPMENT
Mononuclear phagocytic cells, termed macrophages,
play an important role as scavengers, microbicidal
effectors, and regulatory cells in cardiac inﬂamma-
tion. Cells of the monocyte and macrophage lineages
represent the majority of inﬁltrating inﬂammatory
cells in human and experimental myocarditis. The
spleen is an important reservoir of monocytic pre-
cursors in inﬂammatory conditions. Cardiac injury
upon myocarditis results in early recruitment of
Ly6Chi inﬂammatory macrophages (80,81). Blockadeof chemokines associated with the recruitment of
Ly6Chi inﬂammatory monocytes, such as the CCR2
ligands CCL2/MCP1 or CCL3/MIP1a, ameliorates
autoimmune myocarditis (82,83).
CD4þ T (type 1 T helper [Th1]) cells strongly inﬂu-
ence the functional differentiation of monocytes to-
ward proinﬂammatory or classical M1 macrophages
(84). The Th1 IFN-g potentiates the microbicidal ac-
tivity of macrophages and, as such, promotes antigen
presentation (85).
Alternatively-activated Ly6Clow M2 macrophages
predominate during the process of myocardial heal-
ing (86,87). These M2 macrophages blunt the in-
ﬂammatory response and promote cardiac ﬁbrotic
healing (68,86). Here, Th2-associated cytokines,
mainly IL-4 and -13, activate the anti-inﬂammatory
M2 macrophage phenotype (87). These M2 cells are
also hallmarks of the transition from acute myocar-
ditis to chronic pathological remodeling, where the
macrophages are replaced by proﬁbrotic myoﬁbro-
blasts (88,89). Overall, macrophage phenotypes
in vivo are variable, due to their high plasticity and
capacity to adopt varying degrees of specialization,
including microbicidal activity, antigen presentation,
immunoregulation, and ﬁbrosis, depending on the
local cytokine and chemokine milieu.
ROLE OF T-CELL SUBSETS IN MYOCARDITIS
T cells play a central role in the development of
myocarditis, despite the fact that they account for a
minority of heart inﬁltrating cells in mouse models
of myocarditis, as well as biopsy-proven human
myocarditis (90). CD4þ, as well as gd T cells, CD8þ
T-cell, and NK cell responses are critical to overcome
early acute viral infections in rodents and humans
(53,91,92). Importantly, T-cell responses, in partic-
ular CD4þ cells, can turn initial myocarditis into an
autoimmune response, even after clearance of the
infectious agent (56), in part due to thymic intoler-
ance to alpha-myosin heavy chain (a-MyHC) (93).
Activated, self-antigen–expressing dendritic cells
promote expansion of autoreactive CD4þ T-cells and
heart-speciﬁc inﬂammation (39,94). Transgenic mice
overexpressing a-MyHC–speciﬁc T-cell receptors
(TCR) in nearly all CD4þ T cells develop spontaneous
autoimmune myocarditis, even in the presence of
minimal antigen-presenting cell activation (95).
CD4þ effector T cells can be divided into 3 major
subsets, according to the cytokines they produce: Th1
CD4þ cells mainly produce IFN-g; Th2 CD4þ T cells
mainly produce IL-4, -5, and -13; and Th17 CD4þ T
cells mainly produce IL-17. Those subsets play
distinct roles in myocarditis and its progression to
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2354DCM (45,96–98). IFN-g–producing CD4þ T cells pre-
dominate in autoimmune myocarditis in mice and
human patients, the latter in a-MyHC–responding
CD4þ T cells. Also, IFN-g–overexpressing mice
develop spontaneous cardiac inﬂammation (95).
These ﬁndings all point toward a crucial role of IFN-g–
producing T1 CD4þ cells in myocarditis.
Besides promoting inﬂammation, IFN-g has a par-
adoxical role in preventing exaggerated inﬂamma-
tion, as mice undergoing viral, parasitic, and
autoimmune myocarditis in its absence present with
increased cardiac inﬂammation (99–101). Mechanisti-
cally, IFN-g is a key mediator of a negative feedback
loop limiting activated T-cell expansion. IFN-g pro-
motes nitric oxide production by TipDCs, a distinct,
monocyte-derived CD68þCD11bhiCD11cþ dendritic cell
subset (102). Nitric oxide directly induces apoptosis of
activated Th1 and Th17 effector helper cell subsets.
Th17 cells have been recognized as an important
effector T-cell population in myocarditis. Il-17
depletion results in decreased severity of autoim-
mune myocarditis in mice (54,103). However, its
complete absence in IL-17A knockout mice does not
affect myocarditis (104), but is associated with a sig-
niﬁcant reduction in cardiac ﬁbrosis and progression
to DCM (104). Also, mice lacking IL-23 or signal
transducer and activator of transcription 3, critical for
Th17 differentiation, have reduced severity of
myocarditis (97,100). Taken together, Th17 cells and
associated cytokines appear as major drivers mainly
in chronic myocarditis. Importantly, the cardiac
myosin-Th17 response promotes heart failure in hu-
man myocarditis (105). In contrast, Th1 cells play a
dual role: as mediators in early autoimmune T
effector cell expansion, and as regulators through a
negative feedback mechanism that protects from
overwhelming cardiac inﬂammation.
Finally, heart-speciﬁc, T-helper, cell-dependent
immunoglobulin G autoantibodies are present in hu-
man and rodent myocarditis and in DCM. Their
presence predicts the outcome of DCM patients
(106–109). Anti–beta-1 adrenoceptor antibodies are
detected in up to 38% of DCM patients (110) and
predict the development of cardiac dysfunction in
relatives of DCM patients (107). To better understand
the role of autoantibodies in myocarditis, compari-
sons of patient outcomes with and without myocar-
ditis will be needed.
SEX DIFFERENCES IN MYOCARDITIS AND
INFLAMMATORY CARDIOMYOPATHY
Men are diagnosed with myocarditis more often and
have a worse prognosis than women, perhaps due to amore pronounced ﬁbrotic response (111). A key
question is whether this difference can lead to sex-
speciﬁc therapies for acute and chronic myocarditis.
In murine models, male subjects have increased
coxsackie B3–induced myocarditis compared with
females, due to differences in innate immune re-
sponses to coxsackie B3, rather than increased viral
replication (112,113). Male mice have increased gd T
cells; increased TLR4þ CD11bþ inﬂammation,
including macrophages, neutrophils, mast cells, and
DCs; and an increased Th1 response compared with
females (114). In contrast, protective Th2 responses,
increased B cells, more inhibitory Tim-3þ CD4þ T
cells, and more T regulatory cells dominate the pic-
ture in female animals (114,115). Consistent with these
ﬁndings, intracardiac macrophages from coxsackie
B3–infected male mice preferentially expressed
inducible nitric oxide synthase, IL-12, TNFa, and
CD16/32, markers associated with M1 activation
(116,117). In contrast, heart-inﬁltrating macrophages
in female animals showed a M2 activation pattern,
including arginase 1, IL-10, and the macrophage
mannose receptor expression. Speciﬁc targets in the
inﬂammasome are under investigation.
POST-TRANSLATIONAL REGULATION OF
INFLAMMATION IN MYOCARDITIS
Epigenetic factors inﬂuence the expression of
polygenetic susceptibility. For example, microribo-
nucleic acids (miRNAs) have emerged as epige-
netic regulators of the cardiac immune response
(Figure 3). miRNAs are noncoding, w21-nucleotide-
long, endogenous, small RNA molecules that
post-transcriptionally regulate gene expression by
imperfectly binding to the 30 untranslated region, the
50 untranslated region, or the coding region within a
gene. A single miRNA can modulate the expression of
transcripts for different active proteins, which are
frequently clustered within a single biological process
or pathway, such as inﬂammation or ﬁbrosis (118,119).
They may also result in new therapies, as miRNAs can
easily be inhibited by their antisense complements
(anti-miRs) injected systemically or locally. For
example, the ﬁrst phase II clinical trial with anti-miRs
against miRNA-122 successfully reduced the RNA load
of hepatitis C virus in patients with chronic hepatitis
C virus infection (120).
Recent translational human and experimental
miRNA expression studies support causal links be-
tween miRNA dysregulation and human myocarditis,
and suggest novel miRNA therapeutic targets.
miRNA-155, -146b, and -21 are up-regulated in hearts
during acute human and murine coxsackie B3
FIGURE 3 Roles for MicroRNAs Involved in Myocarditis
MiR-21, -155, -146b, and -590 increase cardiac inﬂammation and injury in viral and autoimmune myocarditis, whereas the miR-221/222 cluster is protective
against both by reducing viral replication and its resulting proinﬂammatory response. MiR ¼ microRNA.
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2355myocarditis (121). In human right ventricular (RV)
myocarditis samples, a total of 107 miRNAs are
differentially expressed between viral myocarditis
and control hearts. Of these miRNAs, 21 are signiﬁ-
cantly up-regulated and 37 are down-regulated by
more than 1.5-fold. Inhibition of miRNA-155 (121–123),
miRNA-21, and miRNA-146b (124) by systemically
delivered anti-miRs attenuates cardiac inﬂammation
and myocardial damage in CVB3 or autoimmune
myocarditis in mice. Cardiac overexpression of miR-
590-3p reduced cardiac injury and dysfunction: it
inhibits cardiac nuclear factor–kB p50 expression,
suppresses nuclear factor–kB activity, and blocks
IL-6/TNF-a expression. Furthermore, in a murine
model of Trypanosoma cruzi–induced myocarditis,
expression of 113 of 641 miRNAs was signiﬁcantly
altered. miR-146b, miR-21, miR-142-3p, miR-142-5p,
miR-145-5p, and miR-149-5p correlated with the
severity of the disease (125), and are potential thera-
peutic targets for immunomodulation.
The miRNAs may also modulate the virulence of
cardiotropic viruses. Following cardiac infection, the
enterovirus CVB3 enters the cardiomyocytes via the
coxsackie and adenovirus receptor, replicates, andactivates immune pathways. The miRNA-221/222
cluster in cardiomyocytes regulates both virulence
and inﬂammatory pathways in the heart (126). Sys-
temic inhibition of miR-221/-222 in mice increases
cardiac viral load, prolongs the viremic state,
and aggravates cardiac inﬂammation and injury.
miR-221/-222 works through targeting proteins that
orchestrate viral replication and inﬂammation,
including ETS1/2, interferon regulatory factor 2, Bcl2-
like 11, TOX, Bcl2 modifying factor, and CXCL12.
Similarly, miRNA-155 inhibits PU.1 and suppressor of
cytokine signaling 1 in the heart and, as such, de-
represses the production of proinﬂammatory cyto-
kines, enhancing T-cell and monocyte activation
(126,127). Together, these results support the
concept that a single miRNA or cluster may orches-
trate immune activation and modulate myocarditis.
The miRNAs are under investigation as tools for
myocarditis diagnosis and prognosis. In blood,
miRNAs reﬂecting cardiomyocyte injury (including
miRNA-208 and -499) are increased in acute
myocarditis (128). These cardiomyocyte injury
markers are not speciﬁc for myocarditis, but are
also increased in acute ischemic or hypertensive
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miRNAs, including miRNA-155, -146b, and -21, did not
increase in blood in acute myocarditis (128), possibly
reﬂecting the lack of cellular release of those miRNAs
upon inﬂammation. In a recent study comparing
cardiac miRNA proﬁles in myocarditis patients with
CVB3 persistence to CVB3 clearance, 8 miRNAs (miR-
135b, -155, -190, -422a, -489, -590, -601, and -1290)
were strongly induced only in the hearts of patients
with late viral persistence and progressive cardiac
dysfunction (130). Proﬁling of miRNA groups together
with their messenger RNA/protein targets in cardiac
biopsies is an area of active investigation.
CLINICAL PRESENTATIONS AND PROGRESS
IN CARDIAC IMAGING
Acute myocarditis most commonly presents with
chest pain or dyspnea. A viral syndrome, such as an
upper respiratory tract or gastrointestinal illness,
often precedes the clinical syndrome by several days
to weeks. Chest pain syndromes may be broadly
divided into those resembling pericarditis, with an
associated rise in troponin, and those resembling an
acute myocardial infarction. Angina may be due to
coronary vasospasm or microvascular dysfunction.
Myopericarditis recurs in about 11% of patients
(131). Palpitations and syncope may result from
ventricular arrhythmias. Men have, on average, a
more severe course with less complete recovery than
women (112).
When myocarditis is suspected, we recommend
use of the diagnostic algorithm illustrated in Figure 4.
EMB should be performed if the patient requires
inotropic or mechanical circulatory support, develops
Mobitz type 2 second-degree or higher heart block,
has sustained or symptomatic ventricular tachy-
cardia, or fails to respond to guideline-based medical
management within 1 to 2 weeks. Disorders that have
a greater likelihood of high-grade heart block or
ventricular tachycardia include GCM, CS, and necro-
tizing eosinophilic myocarditis. Other clinical sce-
narios where EMB may be useful include suspected
eosinophilic myocarditis and myocarditis associated
with systemic inﬂammatory disorders. If EMB is
infeasible or is not clearly indicated, noninvasive
diagnostic criteria may be used to diagnose probable
acute myocarditis. A diagnosis of probable myocar-
ditis leads to a recommendation to avoid athletics for
at least 3 to 6 months (6) and counseling on the
likelihood of left ventricular (LV) and clinical recov-
ery, discussed later (132). At medical centers with
specialized expertise in myocarditis care, a tailored
evaluation involving specialized studies on biopsytissue or advanced imaging techniques may be
appropriate.
In myocarditis presenting as acute or fulminant
DCM with heart failure, cardiac troponins are often
detectable in blood and can be supportive of the
diagnosis (3). With subacute or chronic myocarditis
presentations, biomarkers of myocardial injury are
usually normal (17,133). We recommend that cardiac
troponin levels be obtained in patients with clinically
suspected acute myocarditis. Although most electro-
cardiographic and echocardiographic changes are
nonspeciﬁc, speckle-tracking–derived strain may
identify early myocarditis (134–136). An echocardio-
gram should be performed in all patients with
clinically suspected myocarditis to exclude hemo-
dynamic, pericardial, and congenital causes of
cardiomyopathy.
Newer sensitive and speciﬁc cardiac magnetic
resonance (CMR) sequences have improved diag-
nostic and prognostic value. T2-weighted CMR se-
quences detect edema or water, and T1-weighted
sequences detect inﬂammation or ﬁbrosis. Standard
tissue characterization by CMR relies on qualitative
visual estimates of signal intensity in native T2-
weighted and post-contrast T1-weighted sequences.
In contrast, native mapping sequences using T1- or T2-
weighted techniques allow for quantitative, repro-
ducible, pixel-level relaxation times that are
compared with standard values derived from normal
subjects. In the largest T1 þ T2 mapping trial to date,
an elevated native T1 yielded the best diagnostic
performance of all CMR parameters in patients with
acute symptoms. In patients with <2 weeks of
symptoms, native T1 yielded the best area under the
receiver-operating characteristic curve (0.82) fol-
lowed by T2 (0.81). The standard Lake Louise Criteria
did not perform as well (0.56). Native T1 had little
value; however, in the chronic (>2 weeks) patient
group, these parameters could not differentiate pa-
tients with inﬂammation from those without (137).
The most typical late gadolinium enhancement
(LGE) pattern in CS consists of multiple, patchy
midmyocardial lesions in a noncoronary (i.e., sparing
the endocardium) distribution with septal and RV
involvement. Diagnostic ﬁndings may fade over
weeks to months (138).
Although LGE imaging can help in distinguishing
nonischemic patterns of myocyte damage and ﬁbrosis
from ischemic injury, T2-weighted and early gado-
linium enhancement imaging detect other inﬂam-
matory features of edema, capillary leakage, and
hyperemia. Myocardial edema in a water-sensitive T2-
weighted sequence is a typical feature of active
inﬂammation. Hyperemia is a regular feature of
FIGURE 4 Algorithm for the Evaluation of Suspected Myocarditis
Unexplained Acute Cardiomyopathy*
Requiring inotropic or mechanical circulatory support, Mobitz type 2 second degree
or higher heart block, sustained or symptomatic ventricular tachycardia or failure to
respond to guideline based medical management within 1-2 weeks?
Yes-Endomyocardial Biopsy
COR I/LOE B
No- Cardiac MRI
COR II/LOE C
Endomyocardial biopsy (EMB) should be performed in those patients with clinically suspected unexplained acute myocarditis who require
inotropic or mechanical circulatory support, Mobitz type 2 second degree or higher heart block, sustained or symptomatic ventricular tachy-
cardia or failure to respond to guideline-directed medical management within 1 to 2 weeks. In other clinical scenarios of clinically suspected
acute myocarditis, EMB may be helpful, but CMR may be considered as an initial diagnostic test to identify inﬂammation. Reprinted with
permission from Bozkurt et al. (176). *Usually a dilated cardiomyopathy. Fulminant myocarditis may have normal end diastolic diameter with
mildly thickened walls. Exclude ischemic, hemodynamic (valvular, hypertensive), metabolic, and toxic causes of cardiomyopathy as indicated
clinically. CMR ¼ cardiac magnetic resonance; COR ¼ Class of recommendation; LOE ¼ Level of Evidence; MRI ¼ magnetic resonance imaging.
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early, regional post-gadolinium enhancement (139).
In acute DCM, CMR features suggestive of
myocarditis predict a greater likelihood of recovery,
deﬁned as a left ventricular ejection fraction (LVEF)
>55% after 24 months (138). In a second study of 37
patients with acute myocarditis, patients with greater
regional or global T2-weighted “edema-sensitive”
sequences also had a signiﬁcant improvement in
LVEF at 12-month follow-up (140). In contrast,
delayed gadolinium enhancement has been associ-
ated with a higher (3.7%/year) risk of a composite of
cardiovascular adverse events. The extent of delayed
gadolinium enhancement also predicted a composite
endpoint of cardiac death, heart failure hospitaliza-
tion, ventricular tachycardia, and sudden death (141).
The extent of myocardial LGE is also inversely
related to survival free of transplantation and life-
threatening ventricular arrhythmias in CS. In 59 pa-
tients with CS (38 women, mean age 46  10 years),
the extent of myocardial LGE, measured as a per-
centage of LV mass; the LV and RV volumes and
ejection fractions; and the thickness of the basal
interventricular septum were determined and
analyzed for prognostic signiﬁcance. In univariate
analysis, myocardial LGE extent predicted event-free
survival, as did scar-like thinning (<4 mm) of thebasal interventricular septum and the ejection frac-
tion of the RV (p < 0.05 for all). In multivariate
analysis, LGE extent remained the only independent
CMR predictor of the composite outcome (hazard
ratio: 2.22 per tertile; 95% conﬁdence interval: 1.07 to
4.59). The extent of LGE >22% (third tertile) had
positive and negative predictive values for the com-
posite endpoints of 75% and 76%, respectively (142).
8F-ﬂuorodeoxyglucose (FDG)-positron emission
tomography (PET) is also useful for detecting active
myocardial inﬂammation, in particular for suspected
CS (143,144). Combining FDG-PET imaging with
myocardial perfusion detects active inﬂammation
and scarring. Early in CS, 18F-FDG-PET may show a
focal FDG increase in the absence of a perfusion
defect. In a more advanced stage, FDG accumulation
may correlate with a perfusion defect. After granu-
lomas have “burned out” or inﬂammation has been
therapeutically suppressed, a perfusion defect may
persist without active inﬂammation. 18F-FDG-PET
imaging may also detect extracardiac inﬂammation
and identify lymph nodes that are amenable to biopsy
(145,146).
In addition to diagnostic use, 18F- FDG-PET can
inform prognosis. Mismatch of FDG and perfusion
measurements predicts adverse cardiac events, and
RV involvement is associated with high risk for
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mismatch or RV involvement had a 3-fold increase in
the rate of adverse events. Newer imaging data from
CMR and PET should be integrated with established
prognostic risk variables, such as QRS width >120 ms,
LVEF, and New York Heart Association functional
class (147,148).
THE ROLE OF EMB
Although EMB is essential for the diagnosis of spe-
ciﬁc histological disorders, the broad use of EMB as a
gold standard has been limited because of cost,
availability of experienced centers, and sensitivity
(3,149). The sensitivity of EMB for GCM is approxi-
mately 80% to 93% (with repeated LV and RV sam-
ples), but is much lower, estimated to be around 20%
to 30%, for more common lymphocytic and sarcoid
myocarditis due to sampling limitations and focal
distribution of sarcoid granuloma and clusters of in-
ﬂammatory cells (12,150). Immunohistochemistry to
visualize speciﬁc inﬂammatory cell types and viral
genome analysis have improved the sensitivity to
40% for DCM. An ESC position statement recom-
mends “immunohistochemical criteria,” such as the
presence of an inﬂammatory inﬁltrate consisting
of $14 leukocytes/mm2, including up to 4 monocytes/
mm2, with the presence of CD3þ T-lymphocytes
$7 cells/mm2 (3). Immunohistochemical criteria seem
to be particularly useful in subacute or chronic
myocarditis, also called inﬂammatory cardiomyopa-
thies, where the rate of normalization of LV function
is only about 20%. LV biopsy increased the yield in
disorders that affect the LV, with a stroke risk of
about 1:300 to 1:500 (151). Intracardiac electrograms
can increase the diagnostic yield of suspected CS
from between 20% and 32% (152,153) to between 60%
and 80% (144,154).
Cardiac biopsies may be used to identify and
quantify viral genomes. Because serological tests
for antiviral antibodies correlate poorly with viral
genomes detected on heart biopsies, serology
cannot be used to substitute for a biopsy-based
diagnosis of viral infection (155). Because viral ge-
nomes may be detected in normal hearts, and in
ischemic and valvular heart disease (156–159), as-
says for replicative RNA intermediates (mRNA for
deoxyribonucleic acid [DNA] viruses) may be
required to deﬁne active infection. For example,
CpG dinucleotide methylation regulates parvo-
virus 19 (PVB19) viral genome expression (160). A
minimum of 4 samples is needed to achieve an
acceptable sensitivity for molecular diagnosis of
erythrovirus PVB19 (161,162).Signiﬁcant cardiac virus presence (possibly related
to the development of cardiac dysfunction) has only
been described for PVB19 (>250 copies/mg DNA) and
for human herpesvirus 6 (>500 copies/mg DNA). Yet,
the simple presence of virus DNA/RNA does not
reﬂect active replication of a virus. Looking for mRNA
intermediates to score active virus replication is still
not part of routine practice. Only a few studies
focused on determining the replicative status of car-
diotropic viruses, mainly for the detection of PVB19
mRNA intermediates (162). Active PVB19 replication
was only seen in cardiac samples with increased
inﬂammation, either in acute myocarditis or chronic
inﬂammatory cardiomyopathy, and was absent in
DCM hearts without inﬂammation. As antiviral ther-
apies have the highest beneﬁt in patients with active
virus replication, its detection would be of great
value, but methods are not yet established, stan-
dardized, or implemented in clinical practice. In the
setting of myocarditis, the presence of multiple viral
genomes has been associated with progression to a
DCM. Clinical studies of the use of molecular assays
for active viral replication to enhance the clinical
beneﬁt of EMB are underway. Other features on EMB
may affect diagnosis and prognosis. GCM may be
distinguished from CS by transcriptome analysis
(163). The severity of necrosis and ﬁbrosis are asso-
ciated with an increased risk of death and transplant
in GCM (164).
HOW TO TREAT MYOCARDITIS?
For all patients with myocarditis presenting as
heart failure with reduced systolic function, we
recommend following the current guidelines and
scientiﬁc statements for heart failure management.
The current guidelines emphasize gradual titra-
tion of neurohormonal-blocking medications, inclu-
ding inhibitors of angiotensin-converting enzyme,
angiotensin-receptor blocking agents, and beta-
blockers, to doses used in clinical trials (165,166).
Tests for speciﬁc causes of myocarditis, such as human
immunodeﬁciency virus, Lyme, or Chagas disease are
indicated in patients who have heightened pre-test
probability. Serological tests for speciﬁc systemic
rheumatological conditions, such as lupus erythema-
tosus, may be useful in select groups. The 2015 Amer-
ican Heart Association/American College of Cardiology
Foundation scientiﬁc statement on sports participa-
tion after myocarditis recommends 3 to 6 months
abstinence from competitive sports. Before clearance,
freedom from exercise-induced arrhythmias and
normalization of heart function should be assessed
with a symptom-limited exercise test, Holter monitor,
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with myocarditis depends on the clinical scenario and:
1) the presence or absence of inﬂammation; 2) the
presence or absence of viral infection; and 3) one of the
speciﬁc histological entities, including GCM, listed in
the following text.
VIRUS-NEGATIVE INFLAMMATION-POSITIVE PATIENTS.
In virus-negative patients with chronic idiopathic
DCM and increased cardiac inﬂammation despite
guideline-directed medical treatment, immunosup-
pression with azathioprine and prednisone for up to
12 months can be an option to improve cardiac
function (167,168). To conﬁrm the positive out-
comes in the ﬁrst randomized single-center studies
using immunosuppression for virus-negative and
inﬂammation-positive DCM (167,168), a multicenter
trial using azathioprine and prednisone for 6 months
is underway (NCT01877746). Enrollment criteria
include more than 6 months of symptoms and a DCM
at the time of screening.
VIRUS-POSITIVE PATIENTS. Viral genome analysis
of EMBs suggests that up to 70% of chronic DCM
patients may carry 1 or more cardiotropic viruses
(10). A study of IFN-b in virus persistence-related
cardiomyopathy, revealed that IFN-b effectively
eliminates enteroviral RNA, with a beneﬁcial effect
on New York Heart Association functional class
(p ¼ 0.013 at follow-up week 12), improvement in
quality of life (Minnesota Heart Failure score;
p ¼ 0.032 at follow-up week 24), and patient global
assessment (follow-up weeks 12 to 24; p ¼ 0.039)
(169). However, one-half of patients spontaneously
eliminated their enterovirus without speciﬁc treat-
ment, suggesting that in addition to the presence of
viral genomes, evidence of active virus replication
should be a criterion for antiviral therapy. Retro-
spective case series indicate that patients with
chronic cardiomyopathy, a higher virus genome
copy number, and evidence of virus replication
may beneﬁt from intravenous immunoglobulin
(IVIG) (170,171). Although IVIG was ineffective for
the treatment of acute DCM in general (172), a
single-center randomized trial using IVIG for
chronic PVB19-related cardiomyopathy to reduce
PVB19 viral load is ongoing (NCT00892112). Chronic
viral infection in the heart can cause chest pain or
heart failure in the absence of cellular inﬂamma-
tion. The clinical term for a cardiac syndrome
associated with being virus genome-positive and
without inﬂammation on biopsy is viral heart dis-
ease (17).
Corticosteroid therapy is the mainstay of immu-
nosuppressive therapy in CS, even though evidenceis on the basis of retrospective observations. Pub-
lished clinical series suggest that corticosteroid
therapy may halt the progression of LV dysfunction,
but there are no data on the effect of immunosup-
pression on survival (173,174). If treatment is initi-
ated early, development of systolic heart failure
seems rare. Observational, uncontrolled data sug-
gest an improvement in LV function with immu-
nosuppression in CS patients with severely impaired
LVEF (<35%) (8). Atrioventricular conduction block
appears to recover in only 10% to 30% of patients
after initiation of steroid therapy.
The treatment of GCM includes immunosuppres-
sion. Since the ﬁrst report of the Multicenter GCM
Study Group, treatment has relied on the combination
of cyclosporine and prednisone, sometimes with
azathioprine (175). Retrospective observations from
the Multicenter GCM Registry and a prospective study
with repeat biopsies suggest that cyclosporine-based
combined immunosuppression attenuates myocar-
dial inﬂammation and improves clinical outcomes
(11). Abrupt cessation of immunosuppression within
the ﬁrst 2 years of treatment has been associated with
fatal disease relapse (36).
High-grade heart block in acute lymphocytic
myocarditis may be temporary and may require only
short-term, transvenous pacing until the acute
inﬂammation subsides. In the setting of likely
reversible LV dysfunction associated with acute
myocarditis, a wearable external deﬁbrillator vest
may be used pending reassessment of LV function.
In contrast, high-grade heart block often is perma-
nent, and is associated with frequent ventricular ar-
rhythmias in CS. The Heart Rhythm Society expert
consensus statement gave a Class IIa recommenda-
tion for an implantable cardioverter-deﬁbrillator in
patients with suspected CS, regardless of LV function
or reversibility of heart block (145).
CONCLUSIONS
In summary, myocarditis represents many diseases
with distinct immunophenotypes. Most advances in
our understanding of inﬂammatory heart disease
pathogenesis have not yet translated into therapeutic
approaches or even better diagnostic tests. Multi-
center trials examining pathway- and pathogen-
speciﬁc treatments are underway presently, using
immunohistochemical and molecular analysis as part
of the enrollment criteria. Peripheral T-cell, DC,
monocyte, and NK-cell activation patterns may differ
in myocarditis compared with noninﬂammatory DCM,
or between different viruses and purely autoimmune
processes. Multiple groups are searching for
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coding or noncoding RNAs for diagnosis and to guide
emerging therapies, such as RNA interference. The
path toward personalized treatment in acute
myocarditis requires deep clinical and immunological
phenotyping. More speciﬁc therapeutic approaches
proposed or under clinical investigation include
individualized antiviral strategies, miRNA-basedgene-silencing strategies, cytokine targeting, and
pharmacological modulation to alter tissue monocytic
precursors of cardiac ﬁbrosis.
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